X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

AMAR REMEDIES LIMITED  (AMAD)


Here is the latest financial fact sheet of AMAR REMEDIES. For more details, see the AMAR REMEDIES quarterly results and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
amar remedies - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 6.1       No. of shares m 26.16
    Mkt Cap Rs m 159       % ch % 0.5
    Vol '000 139.7       % ch week % -7.6
    P/E X -0.5       % ch 1-mth % -18.5
    P/CF X 0.3       % ch 12-mth % -82.7
    EPS (TTM) Rs -12.0       52 week H/L Rs 48.0/5.5
(As on Dec 11, 2013 (Close)) »  Best Performing consumer products Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Jun-08
12
Jun-09
*
12
Jun-10
*
12
Jun-11
*
12
Jun-12
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs583979171164 
Low Rs2113247586 
Sales per share (Unadj.) Rs114.0141.1187.6228.2261.6 
Earnings per share (Unadj.) Rs8.310.212.614.917.4 
Diluted earnings per shareRs8.310.212.614.917.4 
Cash flow per share (Unadj.) Rs9.212.916.619.222.3 
Dividends per share (Unadj.) Rs01.001.001.000 
Adj. dividends per shareRs0.001.001.001.000.00 
Dividend yield (eoy) %03.81.90.80 
Book value per share (Unadj.) Rs47.656.868.383.2100.7 
Adj. book value per shareRs47.656.868.383.2100.7 
Shares outstanding (eoy) m26.1626.1626.1626.1626.16 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.30.20.30.50.5 
Avg P/E ratio x4.72.64.18.27.2 
P/CF ratio (eoy) x4.32.03.16.45.6 
Price / Book Value ratio x0.80.50.81.51.2 
Dividend payout %09.88.06.70 
Avg Mkt Cap Rs m1,0336801,3473,2183,270 
No. of employees `000NANANANANA 
Total wages/salary Rs m8380108128163 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
  INCOME DATA
Net Sales Rs m2,9823,6924,9085,9706,844 
Other income Rs m319111021 
Total revenues Rs m2,9853,7114,9195,9806,865 
Gross profit Rs m3564756868331,131 
Depreciation Rs m2272104110128 
Interest Rs m76124208274398 
Profit before tax Rs m261298385459626 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000-50 
Tax Rs m43325668121 
Profit after tax Rs m218266329391455 
Gross profit margin %11.912.914.014.016.5 
Effective tax rate %16.510.714.514.819.3 
Net profit margin %7.37.26.76.56.6 
  BALANCE SHEET DATA
Current assets Rs m1,2551,7622,4713,3344,904 
Current liabilities Rs m2834766012,4703,581 
Net working cap to sales %32.634.838.114.519.3 
Current ratio x4.43.74.11.31.4 
Inventory Days Days60798593124 
Debtors Days Days83818387100 
Net fixed assets Rs m8401,0821,1621,3821,689 
Share capital Rs m262262262262262 
"Free" reserves Rs m1,0081,2441,5421,9032,358 
Net worth Rs m1,2451,4851,7882,1772,635 
Long term debt Rs m423730275507 
Total assets Rs m2,0952,8463,6334,9286,862 
Interest coverage x4.43.42.92.72.6 
Debt to equity ratio x0000.10.2 
Sales to assets ratio x1.41.31.41.21.0 
Return on assets %14.013.714.813.512.4 
Return on equity %17.517.918.418.017.3 
Return on capital %26.227.732.629.931.0 
Exports to sales %1.33.51.71.34.0 
Imports to sales %00000 
Exports (fob) Rs m381298180273 
Imports (cif) Rs m00000 
Fx inflow Rs m381298180273 
Fx outflow Rs m715412 
Net fx Rs m311147779271 
  CASH FLOW
From Operations Rs m 20 25 -110 -18 -313 
From Investments Rs m -48 -314 -186 -471 -489 
From Financial Activity Rs m 29 295 328 571 769 
Net Cashflow Rs m 0 6 31 82 -33 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for amar remedies limited

 Share Holding
Indian Promoters : 25.5%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 9.2%
FIIs : 0.0%
ADR/GDR : 0.0%
Free float : 65.3%
Shareholders : 13,061
Pledged promoter(s) holding : 99.7%
 Company Information
Top
    REGD OFF: B-G01, Marathon Innova, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
    E-MAIL: investors@amarremedies.com     WEB: www.amarremedies.com
    TELEPHONE: (022) 6556 8091     FAX: NA
    SECTOR: CONSUMER PRODUCTS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
    AUDITOR: Shyam C. Agrawal & Co.
CHM: Pravin N. Shah COMP SEC: Jagdish Nagpal YEAR OF INC: 1984 BSE CODE: 532664 FV (Rs): 10 DIV YIELD (%): -

More consumer products Company Fact Sheets:   NATCO PHARMAIPCA LABSDR. REDDYS LABPIRAMAL ENTERPRISESINDRAPRASTHA MEDICAL


Today's Market

Global Markets Ends the Week Higher on the Back of French Election Results(RoundUp)

Financial markets received a boost earlier in the week by news that centrist Emmanuel Macron had triumphed over far-right candidate Marine Le Pen in the first round of France's presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

We Don't Want More F&O Stocks... We Need Smaller Lot Sizes(Daily Profit Hunter)

Apr 26, 2017

Are you excited to trade in the sixteen new stocks to be introduced in the F&O segment this Friday?

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE AMAR REMEDIES WITH

MARKET STATS